Topical therapy led the actinic keratosis therapies in 2020, driven by easy availability, high target specificity, and deep market penetration. Topical treatments are used for targeting a wide area of visible and invisible lesions on the skin. Also called field therapy, topical treatments have a low risk of scarring. Some of the US Food and Drug Administration (FDA) approved medications for the treatment of actinic keratoses are topical fluorouracil, imiquimod, diclofenac, ingenol mebutate, and combination treatment with medications. Increase in R&D activities will propel the segmental growth. For instance, in December 2020, Athenex, Inc., a multinational biopharmaceutical corporation devoted to the research, production and promotion of innovative cancer treatment treatments and associated disorders, reported that Klisyri (tirbanibulin) has been authorized by the FDA for topical treatment of actinic keratosis (AK) in the face or scalp. Furthermore, promising pipeline drugs such as AM-001, GDC 695, Tirbanibulin, Tuvatexib, etc., and high adoption of combination treatment are the key driving factors in the topical medications segment.

1 INTRODUCTION 

2 EXECUTIVE SUMMARY 

3 MARKET OUTLOOK 

4 INDUSTRY TRENDS 

5 ACTINIC KERATOSIS TREATMENT MARKET THERAPY ANALYSIS

6 ACTINIC KERATOSIS TREATMENT MARKET DRUG CLASS ANALYSIS 

7 ACTINIC KERATOSIS TREATMENT MARKET APPLICATION ANALYSIS 

8 GLOBAL ACTINIC KERATOSIS TREATMENT REGIONAL ANALYSIS

9 MARKET PLAYERS